🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.

RecruitingNAAges 18 Years - anyAllThe University of Texas Medical Branch, Galveston
NCT05147831 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and its incidence varies from 2% to 50% depending on patient risk factors; in addition, studies have shown that CI-AKI occurs in 2% to 25% of patients undergoing coronary intervention. CI-AKI is associated with significant mortality and morbidity in patients undergoing coronary angiography or other diagnostic contrast studies. We assessed the latest promising evidence on the ability of remote ischemic preconditioning (RIPC) to reduce the incidence of CI-AKI in patients undergoing Coronary Angiogram (CA) or diagnostic contrast studies such as CT angiogram, while at the same time being a non-invasi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * (1) Patients undergoing an interventional or diagnostic radiological procedure in which they receive intravascular contrast, including patients undergoing coronary angiogram +/- percutaneous coronary intervention (PCI) for all clinical indications except those indicated for primary PCI due to STEMI * (2) patients presenting with a renal clearance in the range of less than 60 ml/min/1.73 m2 but not declared ESRD * (3) Patients who are not yet recruited for other pharmacological or medical device clinical trials. Exclusion Criteria: * (1) Age \<18 years * (2) Patient on hemodialysis or peritoneal dialysis * (3) Simultaneous participation in another interventional study * (4) Percutaneous coiling/embolization procedures of the kidney * (5) Impossibility to perform RIPC, caused by pathology in both arms (e.g. dystrophy, recent trauma, chronic wounds) * (6) No written informed consent * (7) Urgent angiography in STEMI * (8) Cardiogenic shock requiring catecholamine infusion * (9) Systolic blood pressure \<80 mmHg * (10) Intra-aortic balloon counter-pulsation * (11) Contrast medium injection within the previous 30 days * (12) Expected impossibility to obtain follow-up data at 6-week follow-up * (13) Patients with Raynaud's disease
💊

What it tests

  • Remote Ischemic Preconditioning
📍

Where

1 site
University of Texas- Medical Branch (UTMB)
Galveston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy